Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25570176 | 1.00 | BCHE (0.49) | BCHESMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL25570418 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRMEN1KMT2AHTT | |
| SCHEMBL25568046 | 0.88 | TSHR (0.49) | BCHESMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL25568049 | 0.88 | TSHR (0.49) | BCHESMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL20381996 | 0.87 | SMN1; SMN2 (0.51) | BCHESMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL13102172 | 0.81 | BCHE (0.65) | BCHESMN1; SMN2KDM2BKDM4E | |
| SCHEMBL20962701 | 0.80 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRMEN1KMT2AHTT | |
| SCHEMBL21486158 | 0.79 | TSHR (0.57) | BCHESMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL25568041 | 0.79 | MEN1 (0.54) | SMN1; SMN2TSHRMEN1KMT2AHTT | |
| SCHEMBL14883715 | 0.78 | KMT2A (0.56) | SMN1; SMN2TSHRMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCHE 4288/4885SMN1; SMN2 2010/4885TSHR 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.